StockpollyBeta
Get App
Popularity #2,887
FATE · NASDAQ · Biotechnology

Fate (FATE)

Develops off-the-shelf iPSC-derived CAR T and CAR NK therapies for autoimmune disease and cancer.

$2.47
vs last close−0.11 (−4.46%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue222732222112
Cost of revenue5555351729426030
Gross profit−3−3−32−32−15−28−2−241−22
484548472146143511363133
Research & development343232353534292726252224
19182117213214111111109
Selling & marketing0000016000000
General & administrative19182117211514111111109
Other expenses−5−5−5−5−35−19−29−4−26000
Operating income−51−48−51−45−52−62−41−37−35−35−33−31
6437510432221
Interest income544544333222
Other non-operating income0−4−3−7−5−15−4−3−2−2−2−1
Income before tax−45−44−48−38−48−52−38−34−32−32−31−30
Net income from continuing operations−45−44−48−38−48−52−38−34−32−32−31−30
Net income−45−44−48−38−48−52−38−34−32−32−31−30
EPS, basic−$0.46−$0.45−$0.47−$0.33−$0.40−$0.44−$0.32−$0.29−$0.27−$0.27−$0.26−$0.25
EPS, diluted−$0.46−$0.45−$0.47−$0.33−$0.40−$0.44−$0.32−$0.29−$0.27−$0.27−$0.26−$0.25
Weighted average shares, basic9999101117118118118119119119120120
Weighted average shares, diluted9999101117118118118119119119120120
EBITDA−47−39−43−34−43−42−34−31−29−29−28−31
Depreciation & amortization555555333330
EBIT−51−44−48−38−48−47−38−34−32−32−31−31